论文部分内容阅读
[目的]观察护肝宁片联合二甲双胍对非酒精性脂肪肝病(NAFLD)的治疗作用。[方法]随机将56例NAFLD患者分成2组,治疗组28例予护肝宁片联合二甲双胍片治疗,对照组28例单用二甲双胍片治疗,疗程3个月。治疗前后测定患者肝功能[丙氨酸氨基转移酶(ALT)、天冬氨酸转氨酶(AST)]、血脂[三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)]、胰岛素抵抗指数(IRI)及B超显像变化。同时观察治疗过程中出现的不良反应。[结果]2组患者治疗后的肝功能、血脂指标及IRI、B超显像变化与治疗前比较除对照组AST、LDL、HDL外,均有明显改善(P<0.05),尤以治疗组的ALT、TG、LDL、HDL下降更为明显(P<0.01)。用药期间2组均未出现显著不良反应。[结论]护肝宁片联合二甲双胍对NAFLD有显著疗效且用药安全。
[Objective] To observe the therapeutic effect of Huganing Tablets combined with metformin on non-alcoholic fatty liver disease (NAFLD). [Methods] 56 patients with NAFLD were randomly divided into two groups. The treatment group was treated with Huganing Tablets combined with metformin tablets, and the control group with 28 cases treated with metformin tablets for 3 months. The liver function (ALT, AST), blood lipid [triglyceride (TG), total cholesterol (TC), low density lipoprotein (LDL) High density lipoprotein (HDL)], insulin resistance index (IRI) and B ultrasound imaging changes. At the same time observe the adverse reactions during treatment. [Results] The changes of liver function, blood lipid index, IRI and B-mode ultrasound in both groups were significantly improved (P <0.05) except for AST, LDL and HDL in the control group before treatment, especially in the treatment group ALT, TG, LDL, HDL decreased more significantly (P <0.01). There were no significant adverse reactions in both groups during the treatment. [Conclusion] Huganing tablet combined with metformin has a significant effect on NAFLD and safety of medication.